Gustav A. Christensen serves as Independent Chairman of the Board of the Company. Gustav Christensen has served as a member of our board of directors since January 2016. Mr. Christensen was most recently the President and Chief Executive Officer and director at Dyax Corp., a biopharmaceutical company, where he worked from April 2007 to February 2016. Prior to joining Dyax, Mr. Christensen was a Managing Director at Apeiron Partners, LLC, a boutique life sciences firm, where he worked from 2005 until 2007. Mr. Christensen received his M.Sc. in Economics from the University of Aarhus (Denmark) and his M.B.A. from Harvard Business School.
As the Independent Chairman of the Board of Morphic Inc, the total compensation of Gustav Christensen at Morphic Inc is $292,516. There are 8 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
Gustav Christensen is 72, he's been the Independent Chairman of the Board of Morphic Inc since 2016. There are 1 older and 18 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
Gustav's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo et Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Inc executives and other stock owners filed with the SEC include: